🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Castration-Resistant Prostate Adenocarcinoma

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer NCT06067841Phase 115 sites📍 Palo Alto📍 Sarasota📍 Boston Bristol-Myers Squibb · Tests: BMS-986460 Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer NCT06145633Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Fludeoxyglucose F-18 Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX Study of DCC-2812 in Participants With Advanced Genitourinary Cancers NCT06966024Phase 18 sites📍 Boston📍 Ann Arbor📍 St Louis Deciphera Pharmaceuticals, LLC · Tests: DCC-2812 Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer NCT06850545n/a1 site📍 Kuopio Kuopio University Hospital REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma NCT07594106Phase 1, Phase 26 sites📍 Goodyear📍 Duarte📍 Tampa Regeneron Pharmaceuticals · Tests: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors NCT03972657Phase 1, Phase 224 sites📍 Gilbert📍 Phoenix📍 Tucson Regeneron Pharmaceuticals · Tests: REGN5678, Cemiplimab Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study NCT06039371Phase 21 site📍 Seattle University of Washington · Tests: Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05113537Phase 1, Phase 21 site📍 San Francisco Vadim S Koshkin · Tests: Abemaciclib, Lutetium Lu 177-PSMA-617 Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma NCT07316686Phase 11 site📍 São Paulo Instituto do Cancer do Estado de São Paulo · Tests: Docetaxel 50mg/m2, Docetaxel 60mg/m2, Docetaxel 75 mg/m², 177Lu-PSMA-I&T A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors NCT05914116Phase 1, Phase 2107 sites📍 Tucson📍 Los Angeles📍 Los Angeles DualityBio Inc. · Tests: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264Phase 1, Phase 233 sites📍 Phoenix📍 Scottsdale📍 Tucson Parabilis Medicines, Inc. · Tests: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion Imaging of Solid Tumors Using 18F-TRX NCT06942104Phase 11 site📍 San Francisco Rahul Aggarwal · Tests: 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Blood Specimen Collection Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial NCT04693377NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide NCT06844383Phase 28 sites📍 Duarte📍 La Jolla📍 Boston Prostate Cancer Clinical Trials Consortium · Tests: Talazoparib with enzalutamide, Talazoparib Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT06616155Phase 1, Phase 23 sites📍 Chicago📍 Ann Arbor📍 Detroit University of Michigan Rogel Cancer Center · Tests: Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Enzalutamide Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer NCT07641049Phase 11 site📍 Shenzhen Beijing Biotech · Tests: ETB-DualNK-01, Fludarabine, Cyclophosphamide Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors NCT05176483Phase 1122 sites📍 Phoenix📍 Tucson📍 Palo Alto Exelixis · Tests: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) NCT07179783Phase 21 site📍 Tianjin Tianjin Medical University Second Hospital · Tests: Sacituzumab Tirumotecan, Tagitanlimab ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials NCT06141993n/a3 sites📍 New York📍 Durham📍 Madison Duke University Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial NCT07698535Phase 21 site📍 Seattle University of Washington · Tests: Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography, Docetaxel, PSMA PET … Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T NCT06134232Phase 231 sites📍 Tuscon📍 Duarte📍 Fresno Dendreon · Tests: Sipuleucel-T Injection Castrate Resistant Prostate Cancer Enhertu Therapy NCT06610825Phase 21 site📍 Washington D.C. Washington D.C. Veterans Affairs Medical Center · Tests: Enhertu Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer NCT06582628Phase 219 sites📍 Bordeaux📍 Brest📍 Lille Fundacion Oncosur · Tests: Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer NCT06801236Phase 113 sites📍 La Jolla📍 Tampa📍 Baltimore Acerand Therapeutics (Hong Kong) Limited · Tests: ACE-232 tablets Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) NCT04704505Phase 22 sites📍 Baltimore📍 Porto Alegre Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: radium-223, Bipolar Androgen Therapy (BAT) A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer NCT07189403Phase 16 sites📍 Sarasota📍 New York📍 Providence Daiichi Sankyo · Tests: DS9051b Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial NCT07200830Phase 3138 sites📍 Anchorage📍 Bakersfield📍 Irvine Alliance for Clinical Trials in Oncology · Tests: Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC) NCT07038304Phase 22 sites📍 Groningen📍 Nijmegen University Medical Center Groningen · Tests: Metastasis directed radiotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy